Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 022561
Company: EMD SERONO INC
Company: EMD SERONO INC
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
|---|---|---|---|---|---|---|---|
| MAVENCLAD | CLADRIBINE | 10MG | TABLET;ORAL | Prescription | AB | Yes | Yes |
Original Approvals or Tentative Approvals
| Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
|---|---|---|---|---|---|---|---|
| 03/29/2019 | ORIG-1 | Approval | Type 3 - New Dosage Form | STANDARD |
Label (PDF)
Letter (PDF) Review |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022561s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/022561Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/022561Orig1s000TOC.html |
Supplements
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert | Note | Url |
|---|---|---|---|---|---|
| 05/10/2024 | SUPPL-11 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022561s011lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/022561Orig1s011ltr.pdf | |
| 02/07/2024 | SUPPL-9 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022561Orig1s009Corrected_lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/022561Orig1s009Corrected_ltr.pdf | |
| 12/06/2023 | SUPPL-7 | Labeling-Medication Guide, Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022561s007lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/022561Orig1s007ltr.pdf | |
| 09/19/2022 | SUPPL-6 | Labeling-Package Insert |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022561s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2022/022561Orig1s006ltr.pdf |
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
|---|---|---|---|---|---|
| 05/10/2024 | SUPPL-11 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022561s011lbl.pdf | |
| 02/07/2024 | SUPPL-9 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022561Orig1s009Corrected_lbl.pdf | |
| 12/06/2023 | SUPPL-7 | Labeling-Medication Guide | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022561s007lbl.pdf | |
| 12/06/2023 | SUPPL-7 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022561s007lbl.pdf | |
| 09/19/2022 | SUPPL-6 | Labeling-Package Insert | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022561s006lbl.pdf | |
| 03/29/2019 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022561s000lbl.pdf |
MAVENCLAD
TABLET;ORAL; 10MG
TE Code = AB
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | RLD | TE Code | Application No. | Company |
|---|---|---|---|---|---|---|---|---|
| CLADRIBINE | CLADRIBINE | 10MG | TABLET;ORAL | Prescription | No | AB | 218425 | APOTEX |
| MAVENCLAD | CLADRIBINE | 10MG | TABLET;ORAL | Prescription | Yes | AB | 022561 | EMD SERONO INC |